What insurance policy changes affect code R47.9?

There are 5 tracked policy changes affecting code R47.9, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code R47.9?

Payers that have issued tracked updates for code R47.9 include: Aetna.

How do I get notified when code R47.9 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code R47.9. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code R47.9?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

R47.9 Insurance Policy Changes

ICD-10 R47.9 is officially defined as "Unspecified speech disturbances." code R47.9 is referenced in 5 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code R47.9 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Aug 18, 2026Medium impact
Melodic Intonation Therapy (CPB 0284, reviewed 2026-04-17)
Aetna considers melodic intonation therapy medically necessary for Broca's (expressive, non-fluent) aphasia when all five selection criteria are met: good auditory comprehension; a well-motivated, emotionally stable member with a good auditory span; poor repetition, even for single words; no evidence of bilateral brain involvement; and non-fluent verbal production with diminished articulator agility and effortful initiation of speech. The policy lists melodic intonation therapy as experimental, investigational or unproven for dysarthria, other types of aphasia, verbal apraxia, neurogenic communication impairments secondary to Parkinson's disease and dementia, and raising trans women's singing and speaking fundamental frequencies, and it lists adjunctive transcranial magnetic stimulation or transcranial brain stimulation with melodic intonation therapy for aphasia as experimental too.
Aetna · Identified Aug 16, 2026Medium impact
Speech Generating Devices (CPB 0437, reviewed 2026-07-01)
Aetna covers speech generating devices (SGDs) as medically necessary durable medical equipment only when a speech-language pathologist (SLP) has completed a formal written evaluation before delivery, and the member has a permanent severe expressive speech disability, such as anarthria, aphasia, aphonia, apraxia or dysarthria, whose speaking needs cannot be met with natural communication methods. Only one SGD or speech generating software program at a time is considered medically necessary per member, and an SGD with multiple interfaces is generally considered not medically necessary. Desktop computers, laptop computers, tablets, smart phones and other devices that are not dedicated SGDs are not covered because they do not meet the definition of DME.
Aetna · Identified Aug 15, 2026Medium impact
Cerebral Perfusion Studies (CPB 0663, reviewed 2026-04-14)
Aetna considers CT perfusion studies of the brain medically necessary for evaluating acute stroke (less than 24 hours), including hemorrhagic stroke, subdural hemorrhage and transient ischemic attacks, for following up cerebral ischemia or infarction, for planning therapy for cervical or intracranial arterial occlusive disease, for identifying cerebral hyperperfusion after revascularization, and for evaluating the vascular status of solid tumors when MRI is degraded by susceptibility artifact. Aetna considers MRI perfusion studies medically necessary for diagnosing and following mass lesions such as glioma, for assessing acute stroke penumbra, and for assessing the hemodynamic significance of cervical or intracranial vascular stenosis and the efficacy of revascularization. Aetna considers CT perfusion experimental, investigational or unproven for indications including confirmation of brain death, differentiation of lung cancer from benign lesions, evaluation of head trauma and evaluation of cerebral vasospasm, and considers MRI perfusion unproven for indications including evaluation of traumatic brain injury, evaluation of persistent pain and prognostication of obstructive sleep apnea.
Aetna · Identified Aug 13, 2026Medium impact
Pediatric Intensive Feeding Programs (CPB 0809, reviewed 2025-12-11)
Aetna considers professional services for pediatric intensive feeding programs medically necessary for infants and children with complex feeding and swallowing disorders when an interdisciplinary team provides the care and every listed condition is met. Those conditions include behavior problems interfering with feeding, a documented diagnosis-specific treatment plan with estimated length of treatment, medical causes of failure to thrive treated without resolving the feeding problem, physician coordination and oversight, one of the listed feeding problems, and no response to initial treatment by a single discipline over a 2-month period. Other indications, such as childhood obesity and Prader-Willi syndrome, are considered experimental, investigational, or unproven, and electrical stimulation for swallowing or feeding disorders is also considered experimental, investigational, or unproven.
Aetna · Identified Aug 12, 2026Medium impact
Optical Coherence Tomography of the Head and Neck (CPB 0928, reviewed 2025-12-30)
Optical coherence tomography (OCT) of the head and neck is considered experimental, investigational or unproven for these uses because their effectiveness has not been established: annual OCT follow-up of thyroid ophthalmopathy after orbital decompression, dynamic OCT for actinic keratosis, endoscopic OCT for tympanoplasty, intra-operative wide-field OCT for deep margins in head and neck surgery, OCT for the middle ear, OCT for diagnosis of oral cancerous lesions, OCT for evaluation of voice disorders, OCT for monitoring radiation-induced skin changes in head and neck cancer, OCT angiography for detecting subclinical low perfusion in giant cell arteritis without manifest ocular involvement and in thyroid-associated ophthalmopathy, and OCT otoscopes for imaging the tympanic membrane and middle ear. CPT 0485T through 0486T, 92133 and 92134 are listed as not covered for the indications in this policy, and so are ICD-10 codes for head and neck cancer, thyroid eye disease, tympanic membrane and middle ear disorders, actinic keratosis, radiation-induced skin changes, giant cell arteritis, voice and resonance disorders, and oral cavity cancer screening.

Watch R47.9

Get one email when a payer policy names R47.9, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Melodic Intonation Therapy (CPB 0284, reviewed 2026-04-17)

Speech Generating Devices (CPB 0437, reviewed 2026-07-01)

Cerebral Perfusion Studies (CPB 0663, reviewed 2026-04-14)

Pediatric Intensive Feeding Programs (CPB 0809, reviewed 2025-12-11)

Optical Coherence Tomography of the Head and Neck (CPB 0928, reviewed 2025-12-30)

What insurance policy changes affect code R47.9?

Which payers have updated policy for code R47.9?

How do I get notified when code R47.9 policy changes?

Why do payers change policies for code R47.9?